migraine
Conditions
Interventions
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Aged between 18 and 65, with no gender restrictions; (2) Meeting the diagnostic criteria for migraine with aura and migraine without aura according to the 2018 International Classification of Headache Disorders, 3rd edition (ICHD-III), and the preventive treatment standards outlined in the 2016 Chinese Guidelines for the Prevention and Treatment of Migraine; (3) Planning to take Tizanidine continuously for a minimum of 3 months; (4) Negative findings in head CT or MRI, and absence of neurological abnormalities in the examination; (5) Participants capable of accurately understanding the researcher's instructions, able to independently or with family assistance complete headache and medication diaries; (6) Willing to provide written informed consent voluntarily.
Exclusion criteria
Exclusion criteria: (1) Patients with uncontrolled hypertension were treated with ß - blockers or a - agonists; (2) Severe infection occurred in the past 6 months; (3) Patients with severe cardiovascular disease (severe heart failure, atrial fibrillation, after cardiovascular interventional surgery), cerebrovascular disease (stroke, cerebrovascular malformation), central nervous system infection, intracranial space occupying lesions, or brain trauma and other diseases (4) Patients with severe primary diseases of liver and kidney hematopoietic system; (5) Patients with cervical spondylosis, otogenic, rhinogenic, odontogenic and other secondary headache; (6) Migraine belongs to drug overuse headache and other special types of migraine (such as ophthalmoplegia, hemiplegia, etc.); (7) In recent 6 months, he has taken other drugs to prevent migraine attack systematically; (8) Combination of alcohol or other drug abusers; (9) Patients with severe mental illness, depression or anxiety disorder; (10) Participants in other clinical trials during the period of participating in this trial; (11) Allergy to the drug or similar drugs; (12) Planned pregnancy, pregnancy and lactation women (13) The investigator judged that it was not suitable to participate in the clinical trial (14) Presence of metals in the body or other contraindications for magnetic tests
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Gene polymorphism;Headache impact test;Tizanidine concentration; | — |
Primary
| Measure | Time frame |
|---|---|
| MRI; | — |
Countries
China
Contacts
Public ContactLei Chen
West China Hospital, Sichuan University
Outcome results
None listed